Global Female Fertility and Pregnancy Rapid Test Market 2017-2021
About Female Fertility and Pregnancy Rapid Test
Female fertility and pregnancy rapid tests are quick diagnostics tests used to qualitatively detect the presence of reproductive hormones such as follicle-stimulating hormone (FSH), luteinizing hormone (LH), and human chorionic gonadotropin (hCG) hormone and to know whether a woman is ovulating or pregnant. Pregnancy rapid tests are diagnostic kits that check for chemical markers related to pregnancy. The tests are carried out in three different formats:midstream, strip, card, and digital.
Technavio’s analysts forecast the global female fertility and pregnancy rapid test market to grow at a CAGR of 4.32% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global female fertility and pregnancy rapid test market for 2017-2021. The report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Female Fertility and Pregnancy Rapid Test Market 2017-2021
Technavio recognizes the following companies as the key players in the global female fertility and pregnancy rapid test market: Alere, bioMérieux, Church & Dwight, and Quidel.
Other Prominent Vendors in the market are: Clinical Guard, Fairhaven Health, Germaine Laboratories, MAP Sciences, Mankind Pharma, PRIMA Lab, Princeton BioMeditech, Wondfo, and Zita West.
Commenting on the report, an analyst from Technavio’s team said: “One trend in the market is increasing demand for home diagnostic kits. The fast-paced lifestyle has increased the working and traveling hours leaving very little time for oneself. This is increasing the demand for products that provide instant results such as home diagnostic kits. Often seen as more convenient and less time-consuming alternative to a trip to the doctor's office, self-testing or home diagnostic and monitoring devices are increasing in sales.”
According to the report, one driver in the market is rise in first-time pregnancy age. The first-time pregnancy age is increasing around the world. Earlier the first-time pregnancy age which was 22-30 years, which has now increased to 27-35 years, globally. The delay in first-time pregnancy age is due to many factors including higher education, interest in pursuing a career, economic pressure, and problems in relationships, thus postponing marriage and motherhood to 30 years and above. Increasing interest in higher education and increased use of contraceptives have resulted in women using long-acting forms of birth control, thus declining unplanned pregnancies.
Further, the report states that one challenge in the market is preference for alternative tests. When pregnancy test kits were introduced in the market, the primary driver was the privacy they offered. However, women are increasingly growing comfortable with obstetricians testing for pregnancy, regardless of their marital status. Apart from this, obstetricians and gynecologists also provide accuracy and guidance, inducing the preference for clinical pregnancy tests over self-tests taken at home. Furthermore, women with other related complications such as concerns related to weight, and are planning to start a family prefer visiting a professional instead of taking a home test. Also, in countries such as the US, preference for clinical tests over pregnancy detection kits is further fueled by young women being eligible for health insurance through the Affordable Care Act.
Alere, bioMérieux, Church & Dwight, and Quidel, Clinical Guard, Fairhaven Health, Germaine Laboratories, MAP Sciences, Mankind Pharma, PRIMA Lab, Princeton BioMeditech, Wondfo, and Zita West.